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Objective: Nowadays recombinant factor VIII is produced in murine cells including in Chi-
nese hamster ovary (CHO) and baby hamster kidney cells (BHK). Previous studies, using the
murine leukemia virus-derived retroviral vector pMFG-FVIII-P140K, modiﬁed two recom-
binant human cell lines, HepG2 and Hek293 to produce recombinant factor VIII. In order
to characterize these cells, the present study aimed to analyze the integration pattern of
retroviral vector pMFG-FVIII-P140K.
Methods: This study used ligation-mediated polymerase chain reaction to locate the site of
viral vector integration by sequencing polymerase chain reaction products. The sequences
were compared to genomic databases to characterize respective clones.
Results: The retroviral vector presented different and non-random proﬁles of integration
between cells lines. A preference of integration for chromosomes 19, 17 and 11 was observed
for HepG2FVIIIdB/P140K and chromosome 9 for Hek293FVIIIdB/P140K. In genomic regions
such as CpG islands and transcription factor binding sites, there was no difference in the
integration proﬁles for both cell lines. Integration in intronic regions of encoding protein
genes (RefSeq genes) was also observed in both cell lines. Twenty percent of integrations
occurred at fragile sites in the genome of the HepG2 cell line and 17% in Hek293.
Conclusion: The results suggest that the cell type can affect the proﬁle of chromosomal
integration of the retroviral vector used; these differences may interfere in the level of
expression of recombinant proteins.o Bra© 2014 Associac¸ã∗ Corresponding author at: Av. Tenente Catão Roxo, 2501 – Monte Alegr
reto, SP, Brazil.
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Introduction
Hemophilia A is an X-linked bleeding disorder caused by
the absence or abnormality of factor VIII (FVIII), a cofactor
necessary to generate ﬁbrin. Deﬁciency of FVIII is the most
common coagulation disorder with an incidence of approx-
imately one in 5000 men; it currently affects about 400,000
people worldwide.1,2 Intravenous administration of plasma-
derived or recombinant FVIII (rFVIII) protein is the most
accepted treatment for bleeding episodes in hemophilic
patients.
The production of recombinant FVIII by biopharmaceuti-
cal industries mostly uses murine cell lines such as Chinese
hamster ovary cells (CHO) and baby hamster kidney cells
(BHK) with many studies having shown the efﬁcacy and
safety of these strains.3–5 However, there are some human
pattern post-translational modiﬁcations which the murine
cell lines are not able to emanate as these cells do not
present the necessary cellular machinery.6,7 An alternative
would be to use human cell lines capable of performing
the post-translational modiﬁcations that occur in the human
body.7
FVIII is one of the most complex proteins produced by
recombinant DNA technology. Although recombinant coag-
ulation factor products have been available in the market
for 20 years,8–10 the heterologous expression of FVIII still
presents some problems such as: gene size, low mRNA
expression, and low protein secretion as most is trapped in
the endoplasmic reticulum. Moreover, all currently approved
recombinant products are produced using murine cells that
have a non-human pattern of post-translational modiﬁca-
tions.
Thiswork generated two human cell lines: HEK293, derived
fromkidney, andHepG2, derived from liver tissueswhichwere
geneticallymodiﬁedusing anewretroviral vector derived from
the murine leukemia virus (MLV). The pMFG-FVIII-P140K vec-
tor contains the human FVIII gene with the B domain deleted
and the selection marker gene (P140K) that confers resistance
to the drugs, O6-benzylguanine and temozolomide. With this
system, high levels of recombinant FVIII were produced in
HepG2 cells (8 IU/mL).
Selecting a human cell line with high productivity of
recombinant FVIII is the ﬁrst step in the future production
of a recombinant protein more similar to that produced by
the human body with a resulting low risk of inhibitory anti-
body development, thereby providing a better quality of life
for hemophiliac patients.
The goal of this studywas to characterize andmap the inte-
gration sites of this new vector in two human cell lines. Highly
sensitive ligation-mediated polymerase chain reaction (LM-
PCR) was combined with sequencing to identify integration
patterns of aMLVvector carrying rFVIII. In thiswork, a detailed
mapping of integration sites of the human cell expression
of recombinant FVIII was performed using a very stringent
selection method. Analyses are very important to understand
the behavior of these viral vectors and whether their inte-
gration sites can inﬂuence the expression of recombinant
proteins.2014;36(3):213–218
Methods
Cell lines and retroviral vector
Human hepatocellular carcinoma cell (HepG2 – ATCC num-
ber HB-8065) and human embryonic kidney cell lines (Hek293
– ATCC number CRL-1573) were transduced with a retro-
virus vector (pMFG-P140K) that contains elements derived
from the Moloney murine leukemia virus (MoMuLV). This is
a bicistronic vector, which can express the P140K resistance
gene and the human B-domain-deleted FVIII coagulation fac-
tor. Stable recombinant human FVIII-producing cell lines were
obtained by highly stringent O6-benzylguanine and temo-
zolomide treatment. The rFVIII expressing cells were named
HepG2FVIIIdB/P140K and Hek293FVIIIdB/P140K.
Factor VIII activity quantiﬁcation
Supernatants were harvested and analyzed for FVIII expres-
sion using a one-stage clotting assay (activated partial
thromboplastin time – aPTT). The FVIII concentrations are
given as international units (IU) as deﬁned by theWorldHealth
Organization; 1 IU/mL FVIII is equivalent to 200ng/mL. Brieﬂy,
a test sample of 100L of FVIII-deﬁcient plasma (Biomerieux,
Durham) was incubated at 37 ◦C with 100L of the APTT
reagent (Platelin® LS – Biomerieux). Clotting was initiated
by the addition of 100L 25mM CaCl2 and clotting times
were determined using the COAG-A-MATE device (Organon
Teknika).
Ligation-mediated polymerase chain reaction
Integration sites were cloned by LM-PCR as previously
described.11 Brieﬂy, genomic DNA was extracted from 3×106
cells digested with MseI and SacI to prevent ampliﬁcation of
internal 5′ long terminal repeat (LTR) fragments, and bound
to a MseI double-strand linker. LM-PCR was performed with
nested primers speciﬁc for the LTR and the linker.11 PCR
products were shotgun-cloned by the TOPO TA cloning kit
(Invitrogen) into libraries of integration junctions which were
sequenced to saturation.
Sequence analysis
The sequences generated were subjected to an initial anal-
ysis using the ChromasPro computer program. In this ﬁrst
stage, only the sequence that contained the adapter sequence
(linker) at one end and the sequence related to the retro-
viral LTR at the other end were selected. The sequences were
converted into Fasta format and sent to the Human Genome
BLAT database12 to analyze the homology of the human
genome.Only sequences that showedover 95%homologywith
sequences stored in the database were considered.
Then, sequenceswere submitted to analysis using the pub-
lic Quickmap tool,13 which allows detailed mapping of local
14range of data on genomic features (genes, transcription start
sites, CpG islands, and TFBS, among others) in a window
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Table 1 – Biological activity of recombinant FVIII in
HepG2FVIIIdB/P140K and Hek293FVIIIdB/P140K cell
lines.
Sample IU/mL
DMEM medium 0.01
Supernatant HepG2 (non-transduced) 0.04
Supernatant Hek293 (non-transduced) 0.12
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tSupernatant HepG2FVIIIdB/P140K 7.90
Supernatant Hek293FVIIIdB/P140K 2.10
f ±250kb around the vector integration site. Moreover, the
trands on either side were analyzed separately and the indi-
idual distance of each feature to the base of integration was
alculated in base pairs.
tatistical analysis
s described by Laufs et al. in 2006, in order to test whether
he number of integrations is equally distributed along the
hromosomes, the chi-squared goodness-of-ﬁt test was used
o analyze whether the observed number of integrations (oi)
rose from a multinomial distribution with speciﬁed expected
ntegrations (ei) for the 24 chromosomes (22 autosomes aswell
s the sex chromosomes, X and Y). The differences obtained
ere highly signiﬁcant as evidenced by the retroviral inser-
ion site in chromosome score (RISC) deﬁned as: (oi−ei)2/ei
alues [oi < ei then RISC score× (−1)].15,16 For the detection of
referred genomic integration sites a cut-off of (oi−ei)2/ei = 3
as set.
Fisher’s exact test was used to determine whether there is
n association between the integrations and the TFBS or CpG
sland regions in the two cell lines (p-value≤0.05).
esults
ctivity analysis of biologically active recombinant factor
III
or the characterization of recombinant cell lines, rFVIII activ-
ty levels were determined as previously detailed.
As shown in Table 1, the HepG2FVIIIdB/P140K and
ek293FVIIIdB/P140K cell lines showed high secretion of
iologically active recombinant FVIII (about 7.9 IU/mL and
.1 IU/mL, respectively).
hromosomal integration pattern
total of 422 cloneswere sequencedofwhich 201werederived
rom HepG2FVIIIdB/P140K and 221 from Hek293FVIIIdB/P140K
ells. Of these, 302 (71.56%) sequences were found in the
uman DNA database with identities ≥98% (123 from HepG2
nd 179 from Hek293 cell lines). The integration sites were
equenced to saturation; these sites began to repeat sub-
equent to the integrations described here. DNA sequences
ere submitted to an analysis using the Quickmap tool,12hich classiﬁes sequences as ‘true’ when they are homol-
gous to only one place in the human genome, or ‘false’
hen sequences are ambiguous, i.e. they are homologous
o more than one location in the genome. Of the 12314;36(3):213–218 215
HepG2FVIIIdB/P140K sequences, 73 were considered true
whereas the remaining 50 were ambiguous. For the 179
Hek293FVIIIdB/P140K sequences, 64 were true and 115 were
ambiguous.
HepG2/FVIIIdBP140K clone sequences showed that inte-
grations occurred in 18 of 23 chromosomes with preference
for speciﬁc chromosomes. For these cells, 19% of the inte-
grations occurred within chromosome 19, followed by 16%
within chromosome 17 and 9.6% within chromosome 11. For
the Hek293FVIIIdB/P140K cells, insertions affected 20 of the 23
chromosomes,withhigh frequencies of integrations occurring
within chromosomes 9 (14%) and X (9%) (Figure 1A).
Statistical analysis of the number of integrations observed
versus expected number of integrations is given by the RISC
score. Using a cut-off of 3, the proﬁles of integration of
retroviral vectors are not random and differ between the
cells studied. For the HepG2 cell line there was a preference
for chromosomes 19 (RISC=94.28), 17 (RISC=49.28) and 11
(RISC=3.44), and for theHEK293 cell line, a preference for chro-
mosome 9 (RISC=10.67) was observed as shown in Figure 1B.
Frequency of integration near transcription factor binding
sites and CpG islands
In this study, a total of 140 TFBS were affected by integrations
that occurred in HepG2FVIIIdB/P140K cells. Of these, ﬁve inte-
grations occurred in areaswithin 5kb, nine integrationswithin
10kb and 39 within 30kb of TFBS. In Hek293FVIIIdB/P140K
kidney cells, a total of 117 TFBS were affected, and only two
insertions occurred within 5kb, one integration within 10kb
and nine within 30kb of TFBS. The integration proﬁles of
TFBS regions showed no statistically signiﬁcant differences
between the two cell lines according to Fisher’s exact test (p-
value=0.606) as shown in Figure 2A.
The distance of integration sites from the next CpG islands
up- or down-stream was also quantiﬁed. Of 73 integrations
of the retroviral vector, 106 CpG islands were affected in
the HepG2 cell line. Of these, 17 occurred in areas within
5kb, eight integrations within 10kb and 25 within 30kb
of CpG islands. Of 64 integrations of the retroviral vector
in Hek293FVIIIdB/P140K kidney cells, 81 CpG islands were
affectedwith six of these insertions occurringwithin 5kb, only
one integration within 10kb and seven within 30kb of CpG
islands. As shown in Figure 2B, there was no statistical dif-
ferences between cell lines related to the integration proﬁles
of the retroviral vector pMFG-FVIII-P140K near CpG islands
(Fisher test; p-value=0.5462).
Analysis of targeted genes
Of the 73 sequences analyzed from HepG2/FVIIIdBP140K cells,
38 (52%) were located in reference sequence (RefSeq) genes.
Of all integrations, only 6% were in exons and 94% were in
intronic regions. For the 64 clones of the Hek293/FVIIIdBP140K
cell line, 28 (44%) were integrated into RefSeq genes; 10% were
in exons and 90% in regions of introns. The frequency of retro-
viral vector insertions in RefSeq genes in HepG2 cells (52%)
was higher than the results generated by a set of 10,000 ran-
dom integrations simulated by the Quickmap program (about
216 rev bras hematol hemoter. 2014;36(3):213–218
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Figure 1 – (A) Integration pattern of retroviral vector pMFG-FVIII-P140K in the 23 chromosomes of two cell lines producing
recombinant factor VIII. (B) RISC score – number of chromosomal integrations observed versus number of expected
IIIdBintegrations of the PMFG-FVIII-P140K vector in the HepG2FV
40%).Hek293 cells showeda similar frequency to that expected
randomly (44%).
For HepG2 cells, of the 38 integrations in RefSeq genes,
the gene with the largest number of insertions (32%) was
the collagen type 1 (COL1A1) gene, followed by the Down syn-
drome cell adhesion molecule (DSCAML1) gene (13%). These genes
are located on chromosomes 17 and 11 respectively. Hek293
cells had a total of 28 integrations in RefSeq genes with 29%
occurring in the PPAPR3 gene, which is part of the lipid phos-
phatases family and is located on chromosome 9.
Integration in fragile sites
When retroviral integrations in fragile sites were analyzed,
the HepG2/FVIIIdBP140K cells showed 20% of integrations
in fragile sites whereas Hek293/FVIIIdBP140K cells showed
around 17%. Fragile sites are classiﬁed into rare and common
according to their frequency and characteristics on chromo-
somes. Integrations were observed in both groups. As shown
in Figure 3, the most affected fragile sites of HepG2 cells were
FRA11G (5.35%) andFRA11B (5.35%),whereas themost affected
sites for Hek293 were FRA2B (3.77%) and FRA1H (3.77%). When
these results are compared with a set of 10,000 random inte-
grations simulated by the Quickmap computer program, there/P140K and Hek293FVIIIdB/P140K cell lines (cut-off = 3).
was a difference in the percentage of integration as the inte-
gration was random; expected frequencies would be 0.18% of
fragile sites for HepG2 and 0.44% for Hek293.
Discussion
The present study aimed to characterize the integration pat-
tern of the retroviral vector pMFG-FVIII-P140K in two cell
lines producing recombinant B-deleted FVIII. The strains used
were grown in artiﬁcial in vitro conditions using culture and
selected by very stringent treatment using chemotherapeutic
drugs (temozolomide and O6-benzylguanine). The integration
proﬁle of the retrovirus described is speciﬁc to these popula-
tions. The cell lines used in this work serve as a model that
may not accurately represent the biology of normal primary
cells.
Through an analysis in the integration sites of the retroviral
vector pMFG-FVIII-P140K, anon-randompatternwasobserved
for both cells since there was a preference for insertion into
speciﬁc chromosomes (19 and 17 in HepG2 and 9 in Hek293) in
a pattern that was not proportional to the size of the chromo-
somes. The distribution of integration sites can be inﬂuenced
by various characteristics of the cell population including the
fact that these cells were selected with high stringency and
rev bras hematol hemoter. 20
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Figure 2 – (A) Number of retroviral vector integrations
observed in regions near to transcription factor binding
sites (TFBS) (p-value=0.606). (B) Number of retroviral vector
integrations observed in regions near to CpG island
(p-value=0.5462).
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have a difﬁcult karyotype to deﬁne.17 The differences in the
integration frequencies between chromosomes are in part a
function of gene density. For example, Mitchell et al. in 2004
described that the gene-rich Chromosome 19 showed more
integration than expected by chance, whereas the gene-poor
Chromosome 18 showed less integration.18 The intracellular
location of the chromosomes can also inﬂuence integration, as
it has been suggested that this is relatively ﬁxed for each cell
type but differs between cell types.18–20 Moreover, retroviral
vector integration into chromosomes with high gene density
could explain why, when the two cell lines were compared in
this study, the expression of rFVIII in HepG2 was almost four
times higher than for HEK293 cells.
The analysis of insertion in genomic regions showed that
for the HepG2 cell line, 52% of the integrations were in genes
encoding proteins, whereas for HEK293 this ﬁgure was 44%.
These results corroborate those of other authors who reported
that the integration of viral vectors derived from MLV are
greater than 45% in cells such as the hematopoietic stem
cells of rhesus monkeys,21 CD34+ cells and HeLa cells.22 It is
worth mentioning that despite the high frequency of integra-
tion within protein-coding genes, more than 90% occurred in
intronic regions in both cell lines. Ustek et al., using next gen-
eration sequencing technology, showed a high frequency of
intragenic integration sites in 293T cells using the lentiviral
vector pLVTHM.23
In regard to the integration into genomic regions, such
as CpG islands and TFBS, the HEK293 and HepG2 cell lines
showed similar integration patterns. However it is interesting
to note that when the distance of retroviral vector integra-
tion was analyzed, the results for integration within 1kb
of CpG islands and TFBS are not in agreement with the
literature11,17,18,24 as most of the integrations occurred at
a distance of between 30 and 60kb. This ﬁnding may be
related to the fact that in most published studies the authors
used infected cells and analyzed the integration within a
 frequency (%)
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maximumof 48handdidnot use any selection strategy, unlike
the present study inwhich the cells remained in a culture after
transduction of the retroviral vector and underwent highly
stringent treatment to select a cell clone producing FVIII.
A study by Russo-Carbolante et al., using the Sk-Hep and
293T cell lines and Green Fluorescent Protein (GFP) for selec-
tion, showed that the lentiviral vectorhaddifferent integration
proﬁles for the two strains.25 However, when analyzing inser-
tion to speciﬁc regions of the genome, such as CpG islands
and transcriptional start sites (TSS), both cells showed similar
integration patterns with over 50% of the integrations occur-
ring at a distance ofwithin 30kb,25 thus in accordancewith the
present study. Since the cells and viral vectors used were dif-
ferent and the integration pattern was similar between cells,
this suggests that it is possible that the selection strategies
used may have an inﬂuence on the identiﬁcation of cell clones
with similar integration sites.
Conclusion
These results show that the vector integration proﬁles of both
cells were different from those described in the literature pos-
sibly because of the use of selection systems. There is evidence
that there is no preferential integration site of the vectorwhen
the integration proﬁles into genomic regions are analyzed.
However, the vector showed non-random patterns of chro-
mosomal integration which differ between the studied cell
lines.
HepG2FVIIIdB/P140K cells expressed higher levels of FVIII
compared to Hek293FVIIIdB/P140K, possibly due to a higher
number of integrations in chromosomes with high gene den-
sity (chromosomes 17 and 19).
Together, these results suggest that cell type can affect
the proﬁle of chromosomal integration of the retroviral vec-
tor used and such discrepancies may interfere in the level of
expression of recombinant proteins.
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